E. Kainne Dokubo
Centers for Disease Control and Prevention
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Kainne Dokubo.
Morbidity and Mortality Weekly Report | 2015
Andrew F. Auld; Ray W. Shiraishi; Francisco Mbofana; Aleny Couto; Ernest Benny Fetogang; Shenaaz El-Halabi; Refeletswe Lebelonyane; Pilatwe T lhagiso Pilatwe; Ndapewa Hamunime; Velephi Okello; Tsitsi Mutasa-Apollo; Owen Mugurungi; Joseph Murungu; Janet Dzangare; Gideon Kwesigabo; Fred Wabwire-Mangen; Modest Mulenga; Sebastian Hachizovu; Virginie Ettiegne-Traore; Fayama Mohamed; Adebobola Bashorun; Do T hi Nhan; Nguyen H uu Hai; Tran H uu Quang; Joelle Deas Van Onacker; Kesner Francois; Ermane Robin; Gracia Desforges; Mansour Farahani; Harrison Kamiru
Equitable access to antiretroviral therapy (ART) for men and women with human immunodeficiency virus (HIV) infection is a principle endorsed by most countries and funding bodies, including the U.S. Presidents Emergency Plan for AIDS (acquired immunodeficiency syndrome) Relief (PEPFAR) (1). To evaluate gender equity in ART access among adults (defined for this report as persons aged ≥15 years), 765,087 adult ART patient medical records from 12 countries in five geographic regions* were analyzed to estimate the ratio of women to men among new ART enrollees for each calendar year during 2002-2013. This annual ratio was compared with estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS)(†) of the ratio of HIV-infected adult women to men in the general population. In all 10 African countries and Haiti, the most recent estimates of the ratio of adult women to men among new ART enrollees significantly exceeded the UNAIDS estimates for the female-to-male ratio among HIV-infected adults by 23%-83%. In six African countries and Haiti, the ratio of women to men among new adult ART enrollees increased more sharply over time than the estimated UNAIDS female-to-male ratio among adults with HIV in the general population. Increased ART coverage among men is needed to decrease their morbidity and mortality and to reduce HIV incidence among their sexual partners. Reaching more men with HIV testing and linkage-to-care services and adoption of test-and-treat ART eligibility guidelines (i.e., regular testing of adults, and offering treatment to all infected persons with ART, regardless of CD4 cell test results) could reduce gender inequity in ART coverage.
PLOS ONE | 2014
E. Kainne Dokubo; Ray W. Shiraishi; Peter W. Young; Joyce J. Neal; John Aberle-Grasse; Nely Honwana; Francisco Mbofana
Objective To determine factors associated with HIV status unawareness and assess HIV prevention knowledge and condom use among people living with HIV/AIDS (PLHIV) in Mozambique. Design Cross-sectional household-based nationally representative AIDS Indicator Survey. Methods Analyses focused on HIV-infected adults and were weighted for the complex sampling design. We identified PLHIV who had never been tested for HIV or received their test results prior to this survey. Logistic regression was used to assess factors associated with HIV status unawareness. Results Of persons with positive HIV test results (N = 1182), 61% (95% confidence interval [CI] 57–65%) were unaware of their serostatus. Men had twice the odds of being unaware of their serostatus compared with women [adjusted odds ratio (aOR) 2.05, CI 1.40–2.98]. PLHIV in the poorest wealth quintile were most likely to be unaware of their serostatus (aOR 3.15, CI 1.09–9.12) compared to those in the middle wealth quintile. Most PLHIV (83%, CI 79–87%) reported not using a condom during their last sexual intercourse, and PLHIV who reported not using a condom during their last sexual intercourse were more likely to be unaware of their serostatus (aOR 2.32, CI 1.57–3.43) than those who used a condom. Conclusions Knowledge of HIV-positive status is associated with more frequent condom use in Mozambique. However, most HIV-infected persons are unaware of their serostatus, with men and persons in the poorest wealth quintile being more likely to be unaware. These findings support calls for expanded HIV testing, especially among groups less likely to be aware of their HIV status and key populations at higher risk for infection.
Lancet Infectious Diseases | 2016
Ishani Pathmanathan; Eric Pevzner; Barbara J. Marston; Shannon Hader; E. Kainne Dokubo
276 www.thelancet.com/infection Vol 16 March 2016 NICE also considered that no evidence showed the eff ectiveness of antibiotic prophylaxis. Although no randomised trial has been done, various observational clinical studies show a benefi t in high-risk groups and data from animal studies show that a single dose of amoxicillin can prevent streptococcal bacteraemia and infective endocarditis. In a 2014 study, 277 prescriptions of antibiotic prophylaxis were needed to prevent one case of infective endocarditis. Numerous studies show a background increase in the incidence of infective endocarditis. However, the above-mentioned 2014 study, showed that the slope of this increase rose in the UK in the years after introduction of the NICE guidance in March, 2008. There has been subsequent debate about the timing of the change in slope and whether the data are better fi tted with a curve than a straight line, but there has been no disagreement about the existence of the change. The study was limited by the absence of microbiological information, and that infective endocarditis-related mortality did not rise in parallel with incidence is surprising. However, the mortality of infective endocarditis caused by oral streptococci is lower than that caused by other organisms, and a US study has shown a rise in infective endocarditis caused by streptococci in the same time period. NICE guidance might seem to simplify dental practice. However, the nature of informed consent obliges dentists to make patients aware of the diff erent guidelines, especially if a patient is at high clinical risk or has a particular concern about antibiotic prophylaxis or infective endocarditis. The dentist would then need to let the patient decide whether or not to receive antibiotic prophylaxis. This process would therefore be much simpler if all guidelines were in agreement. We suggest that the recently updated European Society of Cardiology guidance, remains clinically the most appropriate.
PLOS ONE | 2017
Ishani Pathmanathan; E. Kainne Dokubo; Ray W. Shiraishi; Simon Agolory; Andrew F. Auld; Dennis Onotu; Solomon Odafe; Ibrahim Dalhatu; Oseni Abiri; Henry Debem; Adebobola Bashorun; Tedd V. Ellerbrock
Background Nigeria had the most AIDS-related deaths worldwide in 2014 (170,000), and 46% were associated with tuberculosis (TB). Although treatment of people living with HIV (PLHIV) with antiretroviral therapy (ART) reduces TB-associated morbidity and mortality, incident TB can occur while on ART. We estimated incidence and characterized factors associated with TB after ART initiation in Nigeria. Methods We analyzed retrospective cohort data from a nationally representative sample of adult patients on ART. Data were abstracted from 3,496 patient records, and analyses were weighted and controlled for a complex survey design. We performed domain analyses on patients without documented TB disease and used a Cox proportional hazard model to assess factors associated with TB incidence after ART. Results At ART initiation, 3,350 patients (95.8%) were not receiving TB treatment. TB incidence after ART initiation was 0.57 per 100 person-years, and significantly higher for patients with CD4<50/μL (adjusted hazard ratio [AHR]: 4.2, 95% confidence interval [CI]: 1.4–12.7) compared with CD4≥200/μL. Patients with suspected but untreated TB at ART initiation and those with a history of prior TB were more likely to develop incident TB (AHR: 12.2, 95% CI: 4.5–33.5 and AHR: 17.6, 95% CI: 3.5–87.9, respectively). Conclusion Incidence of TB among PLHIV after ART initiation was low, and predicted by advanced HIV, prior TB, and suspected but untreated TB. Study results suggest a need for improved TB screening and diagnosis, particularly among high-risk PLHIV initiating ART, and reinforce the benefit of early ART and other TB prevention efforts.
Journal of Antimicrobial Chemotherapy | 2017
Gillian Hunt; E. Kainne Dokubo; Tulio de Oliveira; Johanna Ledwaba; Nomathemba Dube; Pravi Moodley; Jennifer Sabatier; Varough Deyde; Lynn Morris; Elliot Raizes
Background KwaZulu-Natal (KZN) Province in South Africa has the highest HIV disease burden in the country, with an estimated population prevalence of 24.7%. A pilot sentinel surveillance project was undertaken in KZN to classify the proportion of adult patients failing first-line ART and to describe the patterns of drug resistance mutations (DRMs) in patients with virological failure (VF). Methods Cross-sectional surveillance of acquired HIV drug resistance was conducted in 15 sentinel ART clinics between August and November 2013. Two population groups were surveyed: on ART for 12-15 months (Cohort A) or 24-36 months (Cohort B). Plasma specimens with viral load ≥1000 copies/mL were defined as VF and genotyped for DRMs. Results A total of 1299 adults were included in the analysis. The prevalence of VF was 4.0% (95% CI 1.8-8.8) among 540 adults in Cohort A and 7.7% (95% CI 4.4-13.0) of 759 adults in Cohort B. Treatment with efavirenz was more likely to suppress viral load in Cohort A (P = 0.005). Independent predictors of VF for Cohort B included male gender, advanced WHO stage at ART initiation and treatment with stavudine or zidovudine compared with tenofovir. DRMs were detected in 89% of 123 specimens with VF, including M184I/V, K103N/S, K65N/R, V106A/M and Y181C. Conclusions VF in adults in KZN was <8% up to 3 years post-ART initiation but was associated with a high frequency of DRMs. These data identify key groups for intensified adherence counselling and highlight the need to optimize first-line regimens to maintain viral suppression.
Emerging Infectious Diseases | 2017
Barbara J. Marston; E. Kainne Dokubo; Amanda van Steelandt; Lise D. Martel; Desmond E. Williams; Sara Hersey; Amara Jambai; Sakoba Keita; Tolbert Nyenswah; John T. Redd
Events such as the 2014–2015 West Africa epidemic of Ebola virus disease highlight the importance of the capacity to detect and respond to public health threats. We describe capacity-building efforts during and after the Ebola epidemic in Liberia, Sierra Leone, and Guinea and public health progress that was made as a result of the Ebola response in 4 key areas: emergency response, laboratory capacity, surveillance, and workforce development. We further highlight ways in which capacity-building efforts such as those used in West Africa can be accelerated after a public health crisis to improve preparedness for future events.
Morbidity and Mortality Weekly Report | 2017
John S. Doedeh; Joseph Asamoah Frimpong; Kwuakuan D.M. Yealue; Himiede W. Wilson; Youhn Konway; Samson Q. Wiah; Vivian Doedeh; Umaru Bao; George Seneh; Lawrence Gorwor; Sylvester Toe; Emmanuel Ghartey; Lawrence Larway; Dedesco Gweh; Philemon Gonotee; Thomas Paasewe; George Tamatai; James Yarkeh; Samuel Smith; Annette Brima-Davis; George Dauda; Thomas Monger; Leleh W. Gornor-Pewu; Siafa Lombeh; Jeremias Naiene; Nathaniel Dovillie; Mark Korvayan; Geraldine George; Garrison Kerwillain; Ralph Jetoh
On April 25, 2017, the Sinoe County Health Team (CHT) notified the Liberia Ministry of Health (MoH) and the National Public Health Institute of Liberia of an unknown illness among 14 persons that resulted in eight deaths in Sinoe County. On April 26, the National Rapid Response Team and epidemiologists from CDC, the World Health Organization (WHO) and the African Field Epidemiology Network (AFENET) in Liberia were deployed to support the county-led response. Measures were immediately implemented to identify all cases, ascertain the cause of illness, and control the outbreak. Illness was associated with attendance at a funeral event, and laboratory testing confirmed Neisseria meningitidis in biologic specimens from cases. The 2014-2015 Ebola virus disease (Ebola) outbreak in West Africa devastated Liberias already fragile health system, and it took many months for the country to mount an effective response to control the outbreak. Substantial efforts have been made to strengthen Liberias health system to prevent, detect, and respond to health threats. The rapid and efficient field response to this outbreak of N. meningitidis resulted in implementation of appropriate steps to prevent a widespread outbreak and reflects improved public health and outbreak response capacity in Liberia.
Morbidity and Mortality Weekly Report | 2016
E. Kainne Dokubo
Tuberculosis (TB) is the leading cause of infectious disease mortality worldwide, accounting for more than 1.5 million deaths in 2014, and is the leading cause of death among persons living with human immunodeficiency virus (HIV) infection (1). Nigeria has the fourth highest annual number of TB cases among countries, with an estimated incidence of 322 per 100,000 population (1), and the second highest prevalence of HIV infection, with 3.4 million infected persons (2). In 2014, 100,000 incident TB cases and 78,000 TB deaths occurred among persons living with HIV infection in Nigeria (1). Nosocomial transmission is a significant source of TB infection in resource-limited settings (3), and persons with HIV infection and health care workers are at increased risk for TB infection because of their routine exposure to patients with TB in health care facilities (3-5). A lack of TB infection control in health care settings has resulted in outbreaks of TB and drug-resistant TB among patients and health care workers, leading to excess morbidity and mortality. In March 2015, in collaboration with the Nigeria Ministry of Health (MoH), CDC implemented a pilot initiative, aimed at increasing health care worker knowledge about TB infection control, assessing infection control measures in health facilities, and developing plans to address identified gaps. The approach resulted in substantial improvements in TB infection control practices at seven selected facilities, and scale-up of these measures across other facilities might lead to a reduction in TB transmission in Nigeria and globally.
PLOS ONE | 2018
Ishani Pathmanathan; Munyaradzi Pasipamire; Sherri L. Pals; E. Kainne Dokubo; Peter Preko; Trong T. Ao; Sikhathele Mazibuko; Janet Ongole; Themba Dhlamini; Samson Haumba
Background Swaziland has the highest adult HIV prevalence and second highest rate of TB/HIV coinfection globally. Recently, the Ministry of Health and partners have increased integration and co-location of TB/HIV services, but the timing of antiretroviral therapy (ART) relative to TB treatment—a marker of program quality and predictor of outcomes—is unknown. Methods We conducted a retrospective analysis of programmatic data from 11 purposefully-sampled facilities to evaluate timely ART provision for HIV-positive TB patients enrolled on TB treatment between July-November 2014. Timely ART was defined as within two weeks of TB treatment initiation for patients with CD4<50/μL or missing, and within eight weeks otherwise. Descriptive statistics were estimated and logistic regression used to assess factors independently associated with timely ART. Results Of 466 HIV-positive TB patients, 51.5% were male, median age was 35 (interquartile range [IQR]: 29–42), and median CD4 was 137/μL (IQR: 58–268). 189 (40.6%) were on ART prior to, and five (1.8%) did not receive ART within six months of TB treatment initiation. Median time to ART after TB treatment initiation was 15 days (IQR: 14–28). Almost 90% started ART within eight weeks, and 45.5% of those with CD4<50/μL started within two weeks. Using thresholds for “timely ART” according to baseline CD4 count, 73.3% of patients overall received timely ART after TB treatment initiation. Patients with CD4 50-200/μL or ≥200/μL had significantly higher odds of timely ART than patients with CD4<50/μL, with adjusted odds ratios of 11.5 (95% confidence interval [CI]: 5.0–26.6) and 9.6 (95% CI: 4.6–19.9), respectively. TB cure or treatment completion was achieved by 71.1% of patients at six months, but this was not associated with timely ART. Conclusions This study demonstrates the relative success of integrated and co-located TB/HIV services in Swaziland, and shows that timely ART uptake for HIV-positive TB patients can be achieved in resource-limited, but integrated settings. Gaps remain in getting patients with CD4<50/μL to receive ART within the recommended two weeks post TB treatment initiation.
Lancet Infectious Diseases | 2018
Catherine H Bozio; Jeni Vuong; E. Kainne Dokubo; Mosoka Fallah; Lucy A McNamara; Caelin C Potts; John Doedeh; Miatta Gbanya; Adam C. Retchless; Jaymin C Patel; Thomas A. Clark; Henry Kohar; Thomas Nagbe; Peter Clement; Victoria Katawera; Nuha Mahmoud; Harouna M Djingarey; Anne Perrocheau; Dhamari Naidoo; Mardia Stone; Roseline N George; Desmond E. Williams; Alex Gasasira; Tolbert Nyenswah; Xin Wang; LeAnne M Fox; Youhn Konway; Samson Q Wiah; Vivian Doedeh; Umaru Bao
BACKGROUND On April 25, 2017, a cluster of unexplained illnesses and deaths associated with a funeral was reported in Sinoe County, Liberia. Molecular testing identified Neisseria meningitidis serogroup C (NmC) in specimens from patients. We describe the epidemiological investigation of this cluster and metagenomic characterisation of the outbreak strain. METHODS We collected epidemiological data from the field investigation and medical records review. Confirmed, probable, and suspected cases were defined on the basis of molecular testing and signs or symptoms of meningococcal disease. Metagenomic sequences from patient specimens were compared with 141 meningococcal isolate genomes to determine strain lineage. FINDINGS 28 meningococcal disease cases were identified, with dates of symptom onset from April 21 to April 30, 2017: 13 confirmed, three probable, and 12 suspected. 13 patients died. Six (21%) patients reported fever and 23 (82%) reported gastrointestinal symptoms. The attack rate for confirmed and probable cases among funeral attendees was 10%. Metagenomic sequences from six patient specimens were similar to a sequence type (ST) 10217 (clonal complex [CC] 10217) isolate genome from Niger, 2015. Multilocus sequencing identified five of seven alleles from one specimen that matched ST-9367, which is represented in the PubMLST database by one carriage isolate from Burkina Faso, in 2011, and belongs to CC10217. INTERPRETATION This outbreak featured high attack and case fatality rates. Clinical presentation was broadly consistent with previous meningococcal disease outbreaks, but predominance of gastrointestinal symptoms was unusual compared with previous African meningitis epidemics. The outbreak strain was genetically similar to NmC CC10217, which caused meningococcal disease outbreaks in Niger and Nigeria. CC10217 had previously been identified only in the African meningitis belt. FUNDING US Global Health Security.